1. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. Issue 8 (22nd November 2022) Authors: Sonneveld, Pieter; Chanan-Khan, Asher; Weisel, Katja; Nooka, Ajay K.; Masszi, Tamas; Beksac, Meral; Spicka, Ivan; Hungria, Vania; Munder, Markus; Mateos, Maria-Victoria; Mark, Tomer M.; Levin, Mark-David; Ahmadi, Tahamtan; Qin, Xiang; Garvin Mayo, Wendy; Gai, Xue; Carey, Jodi; Carson, Robin; Spen... Journal: Journal of clinical oncology Issue: Volume 41:Issue 8(2023) Page Start: 1600 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. Issue 8 (4th January 2023) Authors: Dimopoulos, Meletios A.; Oriol, Albert; Nahi, Hareth; San-Miguel, Jesus; Bahlis, Nizar J.; Usmani, Saad Z.; Rabin, Neil; Orlowski, Robert Z.; Suzuki, Kenshi; Plesner, Torben; Yoon, Sung-Soo; Ben Yehuda, Dina; Richardson, Paul G.; Goldschmidt, Hartmut; Reece, Donna; Ahmadi, Tahamtan; Qin, Xiang; G... Journal: Journal of clinical oncology Issue: Volume 41:Issue 8(2023) Page Start: 1590 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗